Advent of the HIF Stabilizers: Key Considerations for Anemia of CKD Care

Advent of the HIF Stabilizers: Key Considerations for Anemia of CKD Care is organized by Rockpointe Corporation.

Release Date: January 17, 2020
Expiration Date: January 17, 2021

Accreditation:
Physician Credit Designation Statement
Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Designation Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit

Nursing Credit Designation
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Overview:
Hypoxia-inducible factor (HIF) stabilizers are a new class of drugs in late-stage trials that may soon shift the balance of treatment for anemia of chronic kidney disease (CKD). These oral agents are well-tolerated by patients, unlike red-cell transfusions and conventional erythropoiesis-stimulating agents (ESAs). In addition, HIF stabilizers, unlike ESAs, are able to increase hemoglobin (Hgb) levels irrespective of iron supplementation or inflammatory status.

In light of the potential of these groundbreaking emerging therapies, it is critical that nephrology clinicians are aware of the HIF stabilizers and their safety and efficacy data. This educational activity, “Advent of the HIF Stabilizers: Key Considerations for Anemia of CKD Care,” will help participants evaluate the risks and benefits of conventional anemia of CKD treatments, as well as the latest evidence and potential roles of the HIF stabilizers, so that, upon approval, they can be properly incorporated into patient care.

Educational Objectives:
This program is designed to address the following National Academy of Medicine (NAM) competencies: provide patient-centered care and employ evidence-based practice.
• At the conclusion of this activity, participants should be able to:
Evaluate the risks and benefits of ESAs, iron, and blood transfusions in anemia of CKD care
• Assess the most up-to-date evidence and potential roles of the HIF stabilizers in clinical development for the management of anemia of CKD